Simulations Plus Income from Continuous Operations 2010-2024 | SLP
Simulations Plus income from continuous operations from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Simulations Plus Annual Income from Continuous Operations (Millions of US $) |
2024 |
$10 |
2023 |
$10 |
2022 |
$12 |
2021 |
$10 |
2020 |
$9 |
2019 |
$9 |
2018 |
$9 |
2017 |
$6 |
2016 |
$5 |
2015 |
$4 |
2014 |
$3 |
2013 |
$3 |
2012 |
$3 |
2011 |
$3 |
2010 |
$2 |
2009 |
$1 |
Simulations Plus Quarterly Income from Continuous Operations (Millions of US $) |
2024-08-31 |
$1 |
2024-05-31 |
$3 |
2024-02-29 |
$4 |
2023-11-30 |
$2 |
2023-08-31 |
$1 |
2023-05-31 |
$4 |
2023-02-28 |
$4 |
2022-11-30 |
$1 |
2022-08-31 |
$1 |
2022-05-31 |
$4 |
2022-02-28 |
$4 |
2021-11-30 |
$3 |
2021-08-31 |
$0 |
2021-05-31 |
$4 |
2021-02-28 |
$3 |
2020-11-30 |
$2 |
2020-08-31 |
$2 |
2020-05-31 |
$3 |
2020-02-29 |
$2 |
2019-11-30 |
$2 |
2019-08-31 |
$2 |
2019-05-31 |
$3 |
2019-02-28 |
$2 |
2018-11-30 |
$2 |
2018-08-31 |
$1 |
2018-05-31 |
$2 |
2018-02-28 |
$3 |
2017-11-30 |
$2 |
2017-08-31 |
$1 |
2017-05-31 |
$2 |
2017-02-28 |
$1 |
2016-11-30 |
$1 |
2016-08-31 |
$1 |
2016-05-31 |
$2 |
2016-02-29 |
$1 |
2015-11-30 |
$1 |
2015-08-31 |
$0 |
2015-05-31 |
$2 |
2015-02-28 |
$1 |
2014-11-30 |
$1 |
2014-08-31 |
$0 |
2014-05-31 |
$1 |
2014-02-28 |
$1 |
2013-11-30 |
$1 |
2013-08-31 |
$0 |
2013-05-31 |
$1 |
2013-02-28 |
$1 |
2012-11-30 |
$1 |
2012-08-31 |
$0 |
2012-05-31 |
$1 |
2012-02-29 |
$1 |
2011-11-30 |
$1 |
2011-08-31 |
$0 |
2011-05-31 |
$1 |
2011-02-28 |
$1 |
2010-11-30 |
$1 |
2010-08-31 |
$0 |
2010-05-31 |
$1 |
2010-02-28 |
$1 |
2009-11-30 |
$0 |
2009-08-31 |
$0 |
2009-05-31 |
$1 |
2009-02-28 |
$0 |
Sector |
Industry |
Market Cap |
Revenue |
Computer and Technology |
Computer Software |
$0.552B |
$0.070B |
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies.
|